CECAD Microsite

Gero Knittel´s paper on ATM-affected CLL is now online!


The work of Gero Knittel and colleagues, published in Nature Communications, provides a preclinical rational for the use of PARP inhibitors in ATM-affected human CLL.

Chronic lymphocytic leukemia (CLL) remains an incurable disease. Two recurrent cytogenetic aberrations, affecting TP53 and ATM, are associated with resistance against genotoxic chemotherapy and poor outcome. Using two mouse models of Atm- and Trp53-deficient CLL and transcriptome analyses following cyclophosphamide, Gero Knittel and colleagues have shown that Atm deficiency is associated with an exquisite and genotype-specific sensitivity against PARP inhibition.